Choy Bonnie Nga Kwan, Zhu Ming Ming, Shum Jennifer Wei Huen, Ho Wing Lau, Chan Jonathan Cheuk Hung, Ng Alex Lap Ki, Lai Jimmy Shiu Ming
Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Room 301, Block B, Cyberport 4, Hong Kong, SAR, China.
Department of Ophthalmology, Queen Mary Hospital, Hong Kong, SAR, China.
Graefes Arch Clin Exp Ophthalmol. 2016 Mar;254(3):529-33. doi: 10.1007/s00417-015-3245-2. Epub 2015 Dec 21.
To evaluate the effectiveness and safety of collagen crosslinking for leaking cystic blebs.
A prospective study was conducted on subjects with cystic bleb leaks without indications for urgent surgical intervention. Collagen crosslinking with riboflavin 0.1 % and ultraviolet A irradiation for 30 min was applied to the cystic bleb surface in five patients. Subjects were followed up for at least 20 weeks (mean: 35.5 ± 11.5 weeks) to monitor the length of time to the cessation of bleb leak, as well as visual acuity, intraocular pressure, and the presence of adverse effects arising from the treatment.
Results showed that a single session of collagen crosslinking was effective in stopping cystic bleb leak. In two of the five subjects, the bleb leak subsided 1 week post-treatment, in one patient after 2 weeks, and in the two more complicated cases, after 4 weeks. This effect was maintained for a mean period of 33.5 ± 10.2 weeks after bleb leak cessation. Treatment was effective even in patients with friable conjunctiva following multiple surgical interventions and severe leak, although a longer period was needed for resolution of the bleb leak. The intraocular pressure and visual acuity were largely stable before and after treatment. No side effects or complications arose from this treatment.
We recommend a trial of collagen crosslinking on leaking cystic blebs without indications for immediate surgical interventions. It is a relatively easy, non-invasive, pain-free, and potential repeatable procedure for treating leaking cystic blebs, with the aim of strengthening the underlying pathological conjunctiva.
评估胶原交联治疗渗漏性囊性泡的有效性和安全性。
对无紧急手术干预指征的囊性泡渗漏患者进行前瞻性研究。对5例患者的囊性泡表面应用0.1%核黄素和紫外线A照射30分钟进行胶原交联。对受试者进行至少20周(平均:35.5±11.5周)的随访,以监测囊性泡渗漏停止的时间长度,以及视力、眼压和治疗引起的不良反应的发生情况。
结果显示单次胶原交联可有效阻止囊性泡渗漏。5例受试者中,2例在治疗后1周渗漏消退,1例在2周后消退,另外2例情况较复杂的患者在4周后消退。渗漏停止后,这种效果平均维持33.5±10.2周。即使是在多次手术干预后结膜脆弱且渗漏严重的患者中,治疗也是有效的,尽管囊性泡渗漏的消退需要更长时间。治疗前后眼压和视力基本稳定。该治疗未产生副作用或并发症。
对于无立即手术干预指征的渗漏性囊性泡,我们建议尝试胶原交联治疗。这是一种相对简单、无创、无痛且可能可重复的治疗渗漏性囊性泡的方法,旨在强化潜在的病理性结膜。